A specific protein, p92, detected in flat revertants derived from NIH/3T3 transformed by human activated c-Ha-ras oncogene.
Total proteins from a mouse embryo fibroblast cell line NIH/3T3, NIH/3T3 cells transformed by human activated c-Ha-ras (EJ-ras) oncogene (EJ-NIH/3T3), and the two flat revertant cell lines, R1 and R2, were analyzed by two-dimensional gel electrophoresis (IEF and NEPHGE). Several hundred polypeptides were resolved as seen by silver staining. Common alterations in four polypeptide spots were observed in the revertants when compared with NIH/3T3 and EJ-NIH/3T3 cells. In these alterations, a new polypeptide spot p92-5.7 (designated by molecular weight x 10(-3) and pI) was detected only in the revertants and not in NIH/3T3 and EJ-NIH/3T3 cells. Furthermore, the expression level of p92-5.7 seemed to be associated with the flat morphology and the reduced tumorigenicity of the revertants. Polypeptide p92-5.7 was also not detected in the total proteins extracted from BALB/3T3 cells, NIH Swiss mouse primary embryo fibroblasts, NRK (normal rat kidney) cells, and L6 (rat myoblast). Subcellular fractionation of total protein from R1 cells revealed that the p92-5.7 was present in the cytosol. Western blot analysis using an anti-gelsolin antibody demonstrated that the p92-5.7 might be a variant form of gelsolin which is thought to be an actin regulatory protein or a gelsolin-like polypeptide. These results may suggest that the expression of p92-5.7 detected only in the revertants is associated, at least in part, with the reversion. This may be the first demonstration of specific protein expression in the flat revertants.
Fujita
H
H
Cancer Institute, Hokkaido University School of Medicine, Sappore, Japan.
Suzuki
H
H
Kuzumaki
N
N
Müllauer
L
L
Ogiso
Y
Y
Oda
A
A
Ebisawa
K
K
Sakurai
T
T
Nonomura
Y
Y
Kijimoto-Ochiai
S
S
D000818:Animals; D015153:Blotting, Western; D002135:Calcium-Binding Proteins; D002460:Cell Line; D002461:Cell Line, Transformed; D004591:Electrophoresis, Polyacrylamide Gel; D005347:Fibroblasts / Q000032:analysis* / Q000187:drug effects / Q000378:metabolism; D018260:Gelsolin; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008840:Microfilament Proteins; D008970:Molecular Weight; D009363:Neoplasm Proteins / Q000032:analysis* / Q000378:metabolism; D010455:Peptides / Q000032:analysis / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000494:pharmacology*; D016283:Proto-Oncogene Proteins p21(ras); D014335:Tropomyosin / Q000032:analysis
D002135:Calcium-Binding Proteins; D018260:Gelsolin; D008840:Microfilament Proteins; D009363:Neoplasm Proteins; D010455:Peptides; D011518:Proto-Oncogene Proteins; D014335:Tropomyosin; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)